PEGS 2015: Recombinant antibodies for research, diagnosis and therapy
During the PEGS 2015, the Toxab project presented a poster about recombinant antibodies for research, diagnosis and therapy.
Antibodies are promising candidates for basic research, diagnosis and treatment. Currently, multiple monoclonal and recombinant molecules recognizing tumor targets are in preclinical o clinical assays. Accordingly, innovative ones, biosimilars or recombinant fragments with enhanced functions are continuously evolving the state of the art in the field. Our laboratory has a great expertise and experience in antibodies with a clear therapeutic focus aimed principally to oncology.
Several examples are:
- We have generated a number of neutralizing monoclonal antibodies against several members of the S100 protein family; we also proved their therapeutic efficacy in house using particular cellular and animal models leading to the inhibition of tumor growth, tumor metastasis, and tumor angiogenesis in immunodeficient mouse xenograft models of colon, melanoma, pancreatic and other human cancers.
- We have obtained chimeric and humanized versions of these molecules as clinical candidates
- We have generated and characterized several biosimilar antibodies such as anti-VEGF molecules
- We have created site-specific linking ADCs with enhanced cytotoxicity over tumor cells
- We have started new projects involving nanobodies, bispecific antibody fragments and other recombinant multimeric molecules.
It is also important to highlight that in order to characterize all these new monoclonal antibody formats at the analytical, immunological and biological function levels we have two broad in house platforms of in vitro cellular assays and in vivo animal models. LEITAT Biomed invites you to collaborate with us in European projects, services or other platforms in different industrial sectors such as human and veterinarian health, food and environment.
Click here to download the poster
